Using Radialis PET imaging to assess amyloid plaque in the brain
Radialis PET Imager for the Assessment of Neuritic Amyloid Plaque Burden
This study is testing a new type of brain scan called Radialis PET to see if it can measure amyloid plaque in people with cognitive impairment, like Alzheimer's disease, as well as the standard scan.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Health Network, Toronto Academic / other |
| Drugs / interventions | lecanemab, radiation |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT06757569 on ClinicalTrials.gov |
What this trial studies
This study evaluates the Radialis PET imager as an alternative to standard PET imaging for assessing amyloid plaque burden in patients with cognitive impairment, particularly Alzheimer's disease. Given the anticipated increase in demand for amyloid PET scans due to new therapies, this research aims to determine if the Radialis PET imager can provide comparable imaging results. Participants will undergo a standard brain PET scan along with an additional scan using the Radialis PET imager to compare the effectiveness of both imaging methods.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with cognitive impairment who are scheduled for standard brain PET imaging.
Not a fit: Patients who cannot provide informed consent or have contraindications for PET examination will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more accessible and efficient imaging option for patients with cognitive impairment.
How similar studies have performed: While the Radialis PET imager is a novel approach, similar studies have shown the importance of imaging in assessing amyloid burden, but this specific device has not been previously tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years 2. Patients with cognitive impairment undergoing the standard of care brain 18F-Florbetaben PET imaging. 3. Patients who can remain still for an additional scan of approximately 30-45 minutes. \- Exclusion Criteria: 1\. Inability to provide informed consent. 2. Contraindication for PET examination as per institutional safety guidelines, including but not limited to pregnancy or inability to remain still for PET examination. \-
Where this trial is running
Toronto, Ontario
- University Health Network, Toronto — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Study coordinator: Ur Metser
- Email: ur.metser@uhn.ca
- Phone: 416-946-4501
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.